Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Citicoline→

Citicoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
987-78-0
Molecular formula
C14H26N4O11P2
Molecular weight
488.32 g/mol
Drug class
Cytidine-5-diphosphocholine (CDP-choline)phospholipid precursor and neuroactive nutrient
Mechanism of action
An intermediate in the Kennedy pathway for phosphatidylcholine synthesis. After administration it is metabolised to choline and cytidine/uridine, which enter phospholipid and nucleotide pools; proposed neuroprotective effects are not established as a single proven clinical mechanism.
Indications / reported uses
  • No broad FDA- or EMA-authorised therapeutic indication as a standalone medicine. It has been studied or marketed in some countries for stroke, cognitive impairment and neurological recovery, but such uses should be identified as jurisdiction-specific or investigational unless an applicable product label confirms them.

Sources: PubMed — Citicoline pharmacology and clinical evidence · NLM MeSH — Citicoline · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Citicoline Environmental Risk Assessment (ERA) (the Citicoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.